<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-G1WPGRGD</identifier><date>2013</date><creator>Oštrbenk, Anja</creator><creator>Poljak, Mario</creator><relation>documents/doc/G/URN_NBN_SI_doc-G1WPGRGD_001.pdf</relation><relation>documents/doc/G/URN_NBN_SI_doc-G1WPGRGD_001.txt</relation><format format_type="issue">2</format><format format_type="volume">22</format><format format_type="type">article</format><format format_type="extent">str. 43-47</format><identifier identifier_type="ISSN">1318-4458</identifier><identifier identifier_type="COBISSID">30724057</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-G1WPGRGD</identifier><language>eng</language><publisher>Slovene Welding Society</publisher><source>Acta dermatovenerologica Alpina, Pannonica et Adriatica</source><rights>InC</rights><subject language_type_id="eng">cervical cancer</subject><subject language_type_id="eng">human papillomavirus testing</subject><subject language_type_id="slv">validation studies</subject><title>a review of validation studies</title><title>The Abbott RealTime High Risk HPV test is a clinically validated human papillomavirus assay for triage in the referral population and use in primary cervical cancer screening in women 30 years and older</title></Record>